

Food and Drug Administration
Rockville MD 20857

Re: GEMZAR™
Docket No. 96E-0314

JUL - 8 1997

Stephen G. Kunin
Deputy Assistant Commissioner for
Patent Policy and Projects
U.S. Patent and Trademark Office
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JUL 16 1997

PATENT EXTENSION
A/C PATENTS

Dear Mr. Kunin:

This is in regard to the application for patent term extension for U.S. Patent No. 4,808,614 filed by Eli Lilly & Company under 35 U.S.C. § 156.

A letter sent to you dated March 7, 1997 incorrectly stated in the opening paragraph:


The human drug product claimed by the patent is
GEMZAR™ (gemcitabine hydrochloride), which was
assigned New Drug Application (NDA) No. 20-509.

In fact, the statement should have read:

The human drug product identified in the patent extension
application is GEMZAR™ (gemcitabine hydrochloride),
which was assigned New Drug Application (NDA) No.
20-509.

Please let me know if we can be of further assistance.

Sincerely,



Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Margaret Brumm
Eli Lilly & Company
Patent Division/MMB
Lilly Corporate Center
Indianapolis, IN 46285